Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789901 | 0.89 | TP53 (0.55) | ATMALDH1A1TP53SMN1; SMN2CES2 | |
| SCHEMBL10530983 | 0.89 | ALDH1A1 (0.57) | ATMALDH1A1TP53MAPK1ALOX5 | |
| SCHEMBL10525429 | 0.86 | ALDH1A1 (0.72) | ATMALDH1A1TP53MAPK1ALOX5 | |
| SCHEMBL10527468 | 0.85 | ATM (0.56) | ATMALDH1A1TP53MAPK1ALOX5 | |
| SCHEMBL3986259 | 0.81 | ALOX5 (0.50) | ATMALDH1A1TP53MAPK1ALOX5 | |
| SCHEMBL10793831 | 0.80 | ALOX5 (0.48) | ATMALDH1A1ALOX5SMN1; SMN2KDM4E | |
| SCHEMBL1418030 | 0.79 | CES2 (0.54) | ATMALDH1A1SMN1; SMN2CES2PKM | |
| SCHEMBL7055735 | 0.79 | CES2 (0.54) | ATMALDH1A1SMN1; SMN2CES2PKM | |
| SCHEMBL7534105 | 0.79 | CYP3A4 (0.50) | ATMTP53ALOX5SMN1; SMN2CES2 | |
| SCHEMBL698882 | 0.78 | ADRA2C (0.64) | ALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957646-B2 | Methods and compositions of stable phenylephrine formulations | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-04-16 | — | — | US | claimed |
| JP-2008521941-A | — | — | 2008-06-26 | — | — | JP | claimed |
| EP-1819344-A2 | SEPARATION OF FULVESTRANT ISOMERS | Sicor, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070144968-A1 | Separation of fulvestrant isomers | SICOR, INC. | 2007-06-28 | — | — | US | claimed |
| WO-2007044662-A2 | SEPARATION OF FULVESTRANT ISOMERS | SICOR, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20050181496-A1 | Process for preparing purified s-bel and r-bel and compositions thereof | WASHINGTON UNIVERSITY | 2005-08-18 | — | — | US | claimed |
| US-20050118409-A1 | Chelator-modified inorganic oxide particles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-02 | — | — | US | claimed |
| WO-2005037397-A1 | CHELATOR-MODIFIED INORGANIC OXIDE PARTICLES | ZIRCHROM SEPARATIONS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2003079996-A2 | PROCESS FOR PREPARING PURIFIED S-BEL AND R-BEL AND COMPOSITIONS THEREOF | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2003-10-02 | — | — | WO | claimed |
| EP-0567438-B1 | Optically pure cis-oxalato(trans-l-1,2-cyclohexanediamine)Pt(II) and process for resolving optical isomers of a platinum complex compound | TANAKA PRECIOUS METAL IND (JP) | 1999-01-13 | — | — | EP | claimed |
| WO-1998039286-A1 | METHOD FOR OBTAINING α-AMINO ACID ENANTIOMERS AND INTERMEDIATE DIASTEREOISOMERIC SALTS | SANOFI (FR) | 1998-09-11 | — | — | WO | claimed |
| US-5422004-A | Monocyclic or polycyclic aromatic amide moiety; increased enantioselectivity | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-06-06 | — | — | US | claimed |
| US-5420319-A | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | TANAKA KIKINZOKU KOGYO K.K. (JP) | 1995-05-30 | — | — | US | claimed |
| EP-0625523-A1 | Cis-oxalato(trans-L-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | Tanaka Kikinzoku Kogyo K.K. (JP) | 1994-11-23 | — | — | EP | claimed |
| EP-0469739-B1 | Stationary phase for enantiomeric resolution in liquid chromatography | SHIMADZU CORP (JP) | 1994-06-15 | — | — | EP | claimed |
| US-5298642-A | Process of optically resoluting optically active platinum complex compound | TANAKA KIKINZOKU KOGYO K.K. (JP) | 1994-03-29 | — | — | US | claimed |
| WO-1994000408-A1 | HIGH PERFORMANCE CHIRAL SELECTOR | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0567438-A1 | Optically pure cis-oxalato(trans-l-1,2-cyclohexanediamine)Pt(II) and process for resolving optical isomers of a platinum complex compound | Tanaka Kikinzoku Kogyo K.K. (JP) | 1993-10-27 | — | — | EP | claimed |
| US-5149426-A | Stationary phase for enantiomeric resolution in liquid chromatography | SHIMADZU CORPORATION (JP) | 1992-09-22 | — | — | US | claimed |
| EP-0469739-A1 | Stationary phase for enantiomeric resolution in liquid chromatography | SHIMADZU CORPORATION (JP) | 1992-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957646-B2 | Methods and compositions of stable phenylephrine formulations | ADRA2C, ADRA1A, ADRB1 | ATM 4787/4885ALDH1A1 2056/4885TP53 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.